Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 7, 2007 - Issue 12
Submit an article Journal homepage
221
Views
11
CrossRef citations to date
0
Altmetric
Drug Evaluation

Infliximab therapy for pediatric Crohn's disease

Gabor Veres Semmelweis University, 1st Department of Pediatrics, Budapest, Hungary
, MD,
Robert N Baldassano The Children's Hospital of Philadelphia, Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology and Nutrition, 34th Street, Civic Center Boulevard, Philadelphia, PA 19104, USA +1 267 426 5123; +1 215 590 3606; [email protected]
, MD &
Petar Mamula The Children's Hospital of Philadelphia, Center for Pediatric Inflammatory Bowel Disease, Division of Gastroenterology and Nutrition, 34th Street, Civic Center Boulevard, Philadelphia, PA 19104, USA +1 267 426 5123; +1 215 590 3606; [email protected]
, MD
Pages 1869-1880 | Published online: 22 Nov 2007

Bibliography

  • MAMULA P, MARKOWITZ JE, BALDASSANO RN: Inflammatory bowel disease in early childhood and adolescence: special considerations. Gastroenterol. Clin. North Am. (2003) 32:967-995.
  • AUVIN S, MOLINIE F, GOWER-ROUSSEAU C et al.: Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in northern France (1988 – 1999). J. Pediatr. Gastroenterol. Nutr. (2005) 41:49-55.
  • KUGATHASAN SJ, HOFFMANN R, HEIKENEN R et al.: Epidemiologic and characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J. Pediatr. (2003) 143:525-531.
  • HILDEBRAND H, FINKEL Y, GRAHNQUIST L et al.: Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990 – 2001. Gut (2003) 52:1432-1434.
  • CUFFARI C: Inflammatory bowel disease in children: a pediatrician's perspective. Minerva Pediatr. (2006) 58:139-157.
  • GRIFFITHS A, NGUYEN P, SMITH C et al.: Growth and clinical course of children with Crohn's disease. Gut (1993) 34:939-943.
  • MARKOWITZ J, GRANCHER K, KOHN N et al.: A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology (2000) 119:895-902.
  • KIRSCHNER B: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology (1998) 115:813-821.
  • RUTGEERTS P, D'HAENS G, TARGAN S et al.: Efficacy and safety of retreatment with anti-TNF antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology (1999) 117:761-769.
  • RUEMMELE FM: Infliximab: how to use it in pediatric Crohn's disease. J. Pediatr. Gastroenterol. Nutr. (2004) 39:12-14.
  • LOWENBERG M, PEPPELENBOSCH M, HOMMES D: Biological therapy in the management of recent-onset Crohn's disease: why, when and how? Drugs (2006) 66:1431-1439.
  • CAPRILLI R, ANGELUCCI E, COCCO A: Early or late guided missile in the treatment of Crohn's disease? Dig. Liver Dis. (2005) 37:973-979.
  • BALDASSANO RN: Surpassing conventional therapies: the role of biologic therapy. J. Pediatr. Gastroenterol. Nutr. (2001) 33(Suppl. 1):S19-S26.
  • RUTGEERTS P, VAN ASSCHE G, VERMEIRE S: Review article: infliximab therapy for inflammatory bowel disease – seven years on. Aliment. Pharmacol. Ther. (2006) 23:451-463.
  • TARGAN SR, HANAUER SB, VAN DEVENTER SJ et al.: A short-term study of chimeric monoclonal antibody cA2 to TNF-α for Crohn's disease. Crohn's disease cA2 study group. N. Engl. J. Med. (1997) 337:1029-1035.
  • HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 359:1541-1549.
  • RUTGEERTS P, FEAGAN BG, LICHTENSTEIN GR et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 126:402-413.
  • DERKX B, TAMINIAU J, RADEMA S et al.: TNF antibody treatment in Crohn's disease. Lancet (1993) 342:173-174.
  • HOMAN M, BALDASSANO RN, MAMULA P: Managing complicated Crohn's disease in children and adolescents. Nat. Clin. Pract. Gastroenterol. Hepatol. (2005) 2:572-579.
  • Hyams J, Crandall W, Kugathasan S et al.: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology (2007) 132:863-873.
  • BAUMGART DC, SANDBORN WJ: Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet (2007) 369:1641-1657.
  • MULLBERG J, ALTHOFF K, JOSTOCK T et al.: The importance of shedding of membrane proteins for cytokine biology. Eur. Cytokine Netw. (2000) 11:27-38.
  • BRYNSKOV J, FOEGH P, PEDERSEN G et al.: TNF-α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut (2002) 51:37-43.
  • LOUIS E, RIBBENS C, GODON A et al.: Increased production of matrix metalloproteinase-3 and tissue inhibitor of metalloproteinase-1 by inflamed mucosa in inflammatory bowel disease. Clin. Exp. Immunol. (2000) 120:241-246.
  • BREESE EJ, MICHIE CA, NICHOLLS SW et al.: TNF-α-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology (1994) 106:1455-1466.
  • NICHOLLS S, STEPHENS S, BRAEGGER CP et al.: Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J. Clin. Pathol. (1993) 46:757-760.
  • ARDIZZONE S, BIANCHI PORRO G: Inflammatory bowel disease: new insights into pathogenesis and treatment. J. Intern. Med. (2002) 252:475-496.
  • CORNILLIE F, SHEALY D, D'HAENS G et al.: Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with crohn's disease. Aliment. Pharmacol. Ther. (2001) 15:463-473.
  • RUTGEERTS P, VAN ASSCHE G, VERMEIRE S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology (2004) 126:1593-1610.
  • ZEISSIG S, BOJARSKI C, BUERGEL N et al.: Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by TNF-α antibody treatment. Gut (2004) 53:1295-1302.
  • BEGUE B, WAJANT H, BAMBOU JC et al.: Implication of TNF-related apoptosis-inducing ligand in inflammatory intestinal epithelial lesions. Gastroenterology (2006) 130:1962-1974.
  • VAN DEN BRANDE JM, BRAAT H, VAN DEN BRINK GR et al.: Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology (2003) 124:1774-1785.
  • DI SABATINO A, CICCOCIOPPO R, CINQUE B et al.: Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut (2004) 53:70-77.
  • VAN DEN BRANDE JM, KOEHLER TC, ZELINKOVA Z et al.: Prediction of anti-TNF clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut (2007) 56:509-517.
  • ARDIZZONE S, BIANCHI PORRO G: Biologic therapy for inflammatory bowel disease. Drugs (2005) 65:2253-2286.
  • MAMULA P, COHEN SA, FERRY GD et al.: CDP571, a humanized anti-TNF-α monoclonal antibody in pediatric Crohn's disease. Inflamm. Bowel Dis. (2004) 10:723-730.
  • SANDBORN WJ, FEAGAN BG, HANAUER SB et al.: An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology (2001) 120:1330-1338.
  • NESBITT A, FOSSATI G, BERGIN M et al.: Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-TNF-α agents. Inflamm. Bowel Dis. (2007) 13:1323-1332.
  • PAPADAKIS KA, TARGAN SR: TNF: biology and therapeutic inhibitors. Gastroenterology (2000) 119:1148-1157.
  • DANESE S, SANS M, SCALDAFERRI F et al.: TNF-α blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J. Immunol. (2006) 176:2617-2624.
  • BALDASSANO R, BRAEGGER CP, ESCHER JC et al.: Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am. J. Gastroenterol. (2003) 98:833-838.
  • KUGATHASAN S, WERLIN SL, MARTINEZ A et al.: Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am. J. Gastroenterol. (2000) 95:3189-3194.
  • HYAMS JS, MARKOWITZ J, WYLLIE R: Use of infliximab in the treatment of Crohn's disease in children and adolescents. J. Pediatr. (2000) 137:192-196.
  • CEZARD JP, NOUAILI N, TALBOTEC C et al.: A prospective study of the efficacy and tolerance of a chimeric antibody to TNF (remicade) in severe pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. (2003) 36:632-636.
  • BORRELLI O, BASCIETTO C, VIOLA F et al.: Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig. Liver Dis. (2004) 36:342-347.
  • HOMMES D, BAERT F, VAN ASSCHE G et al.: The ideal management of Crohn's disease: top down versus step up strategies, a randomized controlled trial. Gastroenterology (2006) 130(Suppl. II):A749.
  • ROMEO E, VIOLA F, DEANGELIS G et al.: Infliximab as a first choice therapy in children with newly diagnosed Crohn's disease promotes long-term sustained remission and alters the course of the disease. Gastroenterology (2007) 130(Suppl. II):A56.
  • DE RIDDER L, ESCHER JC, BOUQUET J et al.: Infliximab therapy in 30 patients with refractory pediatric Crohn disease with and without fistulas in The Netherlands. J. Pediatr. Gastroenterol. Nutr. (2004) 39:46-52.
  • LIONETTI P, BRONZINI F, SALVESTRINI C et al.: Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment. Pharmacol. Ther. (2003) 18:425-431.
  • LAMIREAU T, CEZARD JP, DABADIE A et al.: Efficacy and tolerance of infliximab in children and adolescents with Crohn's disease. Inflamm. Bowel Dis. (2004) 10:745-750.
  • CANDON S, MOSCA A, RUEMMELE F et al.: Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin. Immunol. (2006) 118:11-19.
  • WEWER V, RIIS L, VIND I et al.: Infliximab dependency in a national cohort of children with Crohn's disease. J. Pediatr. Gastroenterol. Nutr. (2006) 42:40-45.
  • CONDINO AA, FIDANZA S, HOFFENBERG EJ: A home infliximab infusion program. J. Pediatr. Gastroenterol. Nutr. (2005) 40:67-69.
  • PARK SH, JEEN YT, CHUN HR et al.: A case of refractory pediatric Crohn's disease with a successful treatment by infliximab therapy. Korean J. Gastroenterol. (2005) 46:297-301.
  • TEITELBAUM JE, SAEED S, TRIANTAFYLLOPOULOU M et al.: Infliximab in pediatric Crohn disease patients with enterovesicular fistulas. J. Pediatr. Gastroenterol. Nutr. (2007) 44:279-282.
  • BARABINO A, CASTELLANO E, GANDULLIA P et al.: A girl with severe fistulizing Crohn's disease. Dig. Liver Dis. (2000) 32:792-794.
  • REGUEIRO M, MARDINI H: Treatment of perianal fistulizing Crohn's disease with infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm. Bowel Dis. (2003) 9:98-103.
  • KOOROS K, KATZ AJ: Infliximab therapy in pediatric Crohn's pouchitis. Inflamm. Bowel Dis. (2004) 10:417-420.
  • KUGATHASAN S, MIRANDA A, NOCTON J et al.: Dermatologic manifestations of Crohn disease in children: response to infliximab. J. Pediatr. Gastroenterol. Nutr. (2003) 37:150-154.
  • BATRES LA, MAMULA P, BALDASSANO RN: Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J. Pediatr. Gastroenterol. Nutr. (2002) 34:558-560.
  • RAJARAMAN RT, KIMURA Y, LI S et al.: Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology (2006) 113:308-314.
  • QUARTA L, CORRADO A, MELILLO N et al.: Juvenile idiopathic arthritis: an update on clinical and therapeutic approaches. Ann. Ital. Med. Int. (2005) 20:211-217.
  • RICHARDS JC, TAY-KEARNEY ML, MURRAY K et al.: Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin. Exp. Ophthalmol. (2005) 33:461-468.
  • SILBERMINTZ A, KRISHNAN S, BANQUET A et al.: Granulomatous pneumonitis, sclerosing cholangitis, and pancreatitis in a child with Crohn disease: response to infliximab. J. Pediatr. Gastroenterol. Nutr. (2006) 42:324-326.
  • MIELE E, MARKOWITZ JE, MAMULA P et al.: Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J. Pediatr. Gastroenterol. Nutr. (2004) 38:502-508.
  • FARRELL RJ, ALSAHLI M, JEEN YT et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology (2003) 124:917-924.
  • BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. (2003) 348:601-608.
  • SANDBORN WJ: Preventing antibodies to infliximab in patients with Crohn's disease: optimize not immunize. Gastroenterology (2003) 124:1140-1145.
  • VERMEIRE S, NOMAN M, VAN ASSCHE G et al.: Autoimmunity associated with anti-TNF-α treatment in Crohn's disease: a prospective cohort study. Gastroenterology (2003) 125:32-39.
  • HANAUER SB: Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut (2007) 56:1181-1183.
  • VERMEIRE S, NOMAN M, VAN ASSCHE G et al.: Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut (2007) 56:1226-1231.
  • COHEN RD, TSANG JF, HANAUER SB: Infliximab in Crohn's disease: first anniversary clinical experience. Am. J. Gastroenterol. (2000) 95:3469-3477.
  • COHEN RD: Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm. Bowel Dis. (2001) 7(Suppl. 1):S17-S22.
  • JACOBSTEIN DA, MARKOWITZ JE, KIRSCHNER BS et al.: Premedication and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm. Bowel Dis. (2005) 11:442-446.
  • STEPHENS MC, SHEPANSKI MA, MAMULA P et al.: Safety and steroid-sparing experience using infliximab for Crohn's disease at a pediatric inflammatory bowel disease center. Am. J. Gastroenterol. (2003) 98:104-111.
  • FRIESEN CA, CALABRO C, CHRISTENSON K et al.: Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (2004) 39:265-269.
  • CRANDALL WV, MACKNER LM: Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model. Aliment. Pharmacol. Ther. (2003) 17:75-84.
  • KUGATHASAN S, LEVY MB, SAEIAN K et al.: Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction. Am. J. Gastroenterol. (2002) 97:1408-1414.
  • PUCHNER TC, KUGATHASAN S, KELLY KJ et al.: Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction. Inflamm. Bowel Dis. (2001) 7:34-37.
  • VERES G, BALDASSANO RN, MAMULA P: Infliximab therapy in children and adolescents with inflammatory bowel disease. Drugs (2007) 67:1703-1723.
  • COLOMBEL JF, LOFTUS EV Jr, TREMAINE WJ et al.: The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology (2004) 126:19-31.
  • KAMATH BM, MAMULA P, BALDASSANO RN et al.: Listeria meningitis after treatment with infliximab. J. Pediatr. Gastroenterol. Nutr. (2002) 34:410-412.
  • BEHNAM SM, BEHNAM SE, KOO JY: TNF-α inhibitors and congestive heart failure. Skinmed (2005) 4:363-368.
  • REICHARDT P, DAHNERT I, TILLER G et al.: Possible activation of an intramyocardial inflammatory process (Staphylococcus aureus) after treatment with infliximab in a boy with Crohn disease. Eur. J. Pediatr. (2002) 161:281-283.
  • ARMBRUST W, KAMPHUIS SS, WOLFS TW et al.: Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis. Rheumatology (2004) 43:527-529.
  • MYERS A, CLARK J, FOSTER H: Tuberculosis and treatment with infliximab. N. Engl. J. Med. (2002) 346:623-626.
  • KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a TNF-α-neutralizing agent. N. Engl. J. Med. (2001) 345:1098-1104.
  • MOW WS, ABREU-MARTIN MT, PAPADAKIS KA et al.: High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin. Gastroenterol. Hepatol. (2004) 2:309-313.
  • HATEMI G, MELIKOGLU M, FRESKO I et al.: Infliximab does not suppress the tuberculin skin test (purified protein derivative). J. Rheumatol. (2007) 34:474-480.
  • HOMIK J, SUAREZ-ALMAZOR ME, SHEA B et al.: Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst. Rev. (2000) 2:CD000952.
  • LICHTENSTEIN GR, FEAGAN BG, COHEN RD et al.: Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin. Gastroenterol. Hepatol. (2006) 4:621-630.
  • BIANCONE L, ORLANDO A, KOHN A et al.: Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut (2006) 55:228-233.
  • BONGARTZ T, SUTTON AJ, SWEETING MJ et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA (2006) 295:2275-2285.
  • SIEGEL CA, HUR C, KORZENIK JR et al.: Risks and benefits of infliximab for the treatment of Crohn's disease. Clin. Gastroenterol. Hepatol. (2006) 4:1017-1024.
  • THAYU M, MARKOWITZ JE, MAMULA P et al.: Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J. Pediatr. Gastroenterol. Nutr. (2005) 40:220-222.
  • MACKEY AC, GREEN L, LIANG LC et al.: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (2007) 44:265-267.
  • ROSH JR, GROSS T, MAMULA P et al.: Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale? Inflamm. Bowel Dis. (2007) 13:1024-1030.
  • NAVARRO JT, RIBERA JM, MATE JL et al.: Hepatosplenic T-γδ lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk. Lymphoma (2003) 44:531-533.
  • VEGA F, MEDEIROS LJ, GAULARD P: Hepatosplenic and other γδ T-cell lymphomas. Am. J. Clin. Pathol. (2007) 127:869-880.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.